Green Cross' Biologics License Application for IVIG-SN submitted to FDA

November 24, 2015

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration.

Previous Article
Arterial imaging with 3-D MRI could help to determine stroke risk among diabetics
Arterial imaging with 3-D MRI could help to determine stroke risk among diabetics

People with diabetes may be harboring advanced vascular disease that could increase their risk of stroke, a...

Next Article
Green Cross' Biologics License Application for IVIG-SN submitted to FDA
Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted it...